GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Price & Analysis

Compare

5 Followers

GLAXO Stock Chart & Stats

Day’s Range― - ―

52-Week Range₹1,924.30 - ₹3,515.95

Previous CloseN/A

Volume25.42K

Average Volume (3M)3.95K

Market Cap

₹474.25B

Enterprise Value₹462.29B

Total Cash (Recent Filing)₹25.22B

Total Debt (Recent Filing)₹99.50M

Price to Earnings (P/E)49.9

Beta0.85

Next Earnings

Oct 29, 2025

EPS EstimateN/A

Last Dividend Ex-Date

May 30, 2025

Dividend Yield1.93%

Share Statistics

EPS (TTM)12.10

Shares Outstanding169,406,040

10 Day Avg. Volume5,563

30 Day Avg. Volume3,947

Financial Highlights & Ratios

PEG Ratio0.89

Price to Book (P/B)24.28

Price to Sales (P/S)12.64

P/FCF Ratio37.40

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹3,160.00

Price Target Upside12.88% Upside

Rating ConsensusHold

Number of Analyst Covering1

GlaxoSmithKline Pharmaceuticals Limited News

GlaxoSmithKline Pharmaceuticals Enhances Investor Communication

The latest announcement is out from GlaxoSmithKline Pharmaceuticals Limited ( ($IN:GLAXO) ). GlaxoSmithKline Pharmaceuticals Limited has announced the...

25d ago

GLAXO

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Unveils Dividend Details for Q3: Mark Your Calendar!

GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO) has declared, under its dividend policy, a yearly cash dividend in the amount...

3M ago

GLAXO

GLAXO FAQ

What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?

GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹1924.30 and its highest was ₹3515.95 in the past 12 months.

What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?

GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹474.25B.

When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?

GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is Oct 29, 2025 which is in 64 days.

How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?

GlaxoSmithKline Pharmaceuticals Limited released its earnings results on Aug 01, 2025. The company reported ₹12.1 earnings per share for the quarter, beating the consensus estimate of N/A by ₹12.1.

Is GlaxoSmithKline Pharmaceuticals Limited overvalued?

According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?

GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹42 which represents an annual dividend yield of 1.93%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here

What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?

GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?

GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.

What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?

GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹12.1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -7.101%.

Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:GLAXO

Company Description

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) Earnings & Revenues

Historic Earnings Reports

GLAXO Stock 12 Month Forecast

Average Price Target

₹3,160.00

▲(12.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1927":"₹1,927","3352":"₹3,352","2283.25":"₹2,283.3","2639.5":"₹2,639.5","2995.75":"₹2,995.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹3.16K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹3.16K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3160,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹3.16K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1927,2283.25,2639.5,2995.75,3352],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Jan<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3351.4,3336.6769230769232,3321.9538461538464,3307.2307692307695,3292.507692307692,3277.7846153846153,3263.0615384615385,3248.3384615384616,3233.6153846153848,3218.892307692308,3204.169230769231,3189.4461538461537,3174.723076923077,{"y":3160,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3351.4,3336.6769230769232,3321.9538461538464,3307.2307692307695,3292.507692307692,3277.7846153846153,3263.0615384615385,3248.3384615384616,3233.6153846153848,3218.892307692308,3204.169230769231,3189.4461538461537,3174.723076923077,{"y":3160,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3351.4,3336.6769230769232,3321.9538461538464,3307.2307692307695,3292.507692307692,3277.7846153846153,3263.0615384615385,3248.3384615384616,3233.6153846153848,3218.892307692308,3204.169230769231,3189.4461538461537,3174.723076923077,{"y":3160,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1928.87,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2025.58,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2584.96,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2560.5,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2708.09,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2734.03,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2690.94,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2672.62,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2378.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2205.5,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1950.86,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1950.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3351.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >